Zai Lab to present first global data on DLL3 ADC zocilurtatug pelitecan in first-line ES-SCLC trial at ESMO 2026

By Public Technologies
  • Zai Lab flagged first global results from a trial of zocilurtatug pelitecan for first-line extensive-stage small cell lung cancer.
  • Data have not been released yet; an ESMO Congress 2026 poster is scheduled for Oct. 26 in Madrid.
  • The study tests the DLL3-targeting antibody-drug conjugate with atezolizumab, with or without carboplatin.
  • Zai Lab framed the readout as supportive of zocilurtatug pelitecan as a potential backbone therapy in first-line combinations.
  • An investor call is set for Oct. 23 to discuss the ESMO presentation and the program’s next clinical steps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609290700BIZWIRE_USPR_____20260929_BW210432) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.